{"pmid":32368838,"title":"Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single centre cohort of kidney recipients.","text":["Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single centre cohort of kidney recipients.","Since the first cases of Coronavirus Disease 2019(COVID-19) were identified on December 12(th) , 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has dramatically spread worldwide becoming a pandemic with devastating consequences(1) . This exponential increase in COVID-19 cases also includes vulnerable populations such as kidney recipients(2,3) . Although scarce, preliminary information in this population suggests a serious course with a mortality of up to 25%(4) . Herein, we report the outcomes of a cohort of 33 kidney transplant recipients from a single center focusing on hospital and intensive care (ICU) admission and mortality.","Am J Transplant","Montagud-Marrahi, Enrique","Cofan, Frederic","Torregrosa, Josep-Vicens","Cucchiari, David","Ventura-Aguiar, Pedro","Revuelta, Ignacio","Bodro, Marta","Pineiro, Gaston J","Esforzado, Nuria","Ugalde, Jessica","Guillen, Elena","Rodriguez-Espinosa, Diana","Campistol, Josep M","Oppenheimer, Federico","Moreno, Asuncion","Diekmann, Fritz","32368838"],"abstract":["Since the first cases of Coronavirus Disease 2019(COVID-19) were identified on December 12(th) , 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has dramatically spread worldwide becoming a pandemic with devastating consequences(1) . This exponential increase in COVID-19 cases also includes vulnerable populations such as kidney recipients(2,3) . Although scarce, preliminary information in this population suggests a serious course with a mortality of up to 25%(4) . Herein, we report the outcomes of a cohort of 33 kidney transplant recipients from a single center focusing on hospital and intensive care (ICU) admission and mortality."],"journal":"Am J Transplant","authors":["Montagud-Marrahi, Enrique","Cofan, Frederic","Torregrosa, Josep-Vicens","Cucchiari, David","Ventura-Aguiar, Pedro","Revuelta, Ignacio","Bodro, Marta","Pineiro, Gaston J","Esforzado, Nuria","Ugalde, Jessica","Guillen, Elena","Rodriguez-Espinosa, Diana","Campistol, Josep M","Oppenheimer, Federico","Moreno, Asuncion","Diekmann, Fritz"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368838","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/ajt.15970","locations":["Spanish"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138496131137536,"score":9.490897,"similar":[{"pmid":32412159,"title":"First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.","text":["First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.","Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%) and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts.","Am J Transplant","Tschopp, J","L'Huillier, A G","Mombelli, M","Mueller, N J","Khanna, N","Garzoni, C","Meloni, D","Papadimitriou-Olivgeris, M","Neofytos, D","Hirsch, H H","Schuurmans, M M","Muller, T","Berney, T","Steiger, J","Pascual, M","Manuel, O","van Delden, C","32412159"],"abstract":["Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%) and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts."],"journal":"Am J Transplant","authors":["Tschopp, J","L'Huillier, A G","Mombelli, M","Mueller, N J","Khanna, N","Garzoni, C","Meloni, D","Papadimitriou-Olivgeris, M","Neofytos, D","Hirsch, H H","Schuurmans, M M","Muller, T","Berney, T","Steiger, J","Pascual, M","Manuel, O","van Delden, C"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412159","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.16062","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666897319106183168,"score":193.70105},{"pmid":32317402,"title":"Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York.","text":["Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York.","BACKGROUND: The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes. METHODS: We report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes. RESULTS: Patients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up. CONCLUSIONS: Kidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed.","J Am Soc Nephrol","32317402"],"abstract":["BACKGROUND: The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes. METHODS: We report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes. RESULTS: Patients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up. CONCLUSIONS: Kidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed."],"journal":"J Am Soc Nephrol","date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317402","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1681/ASN.2020030375","keywords":["covid-19","epidemiology and outcomes","kidney transplantation","transplant outcomes"],"link_comment_in":"32345701","locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666138493647060993,"score":173.83043},{"pmid":32315122,"title":"COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient.","text":["COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly infecting people worldwide, resulting in the infectious disease coronavirus disease 19 (COVID-19) that has been declared a pandemic. Much remains unknown about COVID-19, including its effects on solid organ transplant (SOT) recipients. Given their immunosuppressed state, SOT recipients are presumed to be at high risk of complications with viral infections such as SARS-CoV-2. Limited case reports in single SOT recipients, however, have not suggested a particularly severe course in this population. In this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite the presence of a number of risk factors for poor outcomes, had a relatively mild clinical course.","Am J Transplant","Hsu, Jeffrey J","Gaynor, Pryce","Kamath, Megan","Fan, Ashley","Al-Saffar, Farah","Cruz, Daniel","Nsair, Ali","32315122"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly infecting people worldwide, resulting in the infectious disease coronavirus disease 19 (COVID-19) that has been declared a pandemic. Much remains unknown about COVID-19, including its effects on solid organ transplant (SOT) recipients. Given their immunosuppressed state, SOT recipients are presumed to be at high risk of complications with viral infections such as SARS-CoV-2. Limited case reports in single SOT recipients, however, have not suggested a particularly severe course in this population. In this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite the presence of a number of risk factors for poor outcomes, had a relatively mild clinical course."],"journal":"Am J Transplant","authors":["Hsu, Jeffrey J","Gaynor, Pryce","Kamath, Megan","Fan, Ashley","Al-Saffar, Farah","Cruz, Daniel","Nsair, Ali"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315122","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15936","topics":["Case Report"],"weight":1,"_version_":1666138493435248640,"score":173.7816},{"pmid":32354634,"pmcid":"PMC7142691","title":"A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.","text":["A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.","The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality.","Kidney Int","Alberici, Federico","Delbarba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Zambetti, Nicole","Moscato, Marianna","Venturini, Margherita","Affatato, Stefania","Gaggiotti, Mario","Bossini, Nicola","Scolari, Francesco","32354634"],"abstract":["The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality."],"journal":"Kidney Int","authors":["Alberici, Federico","Delbarba, Elisa","Manenti, Chiara","Econimo, Laura","Valerio, Francesca","Pola, Alessandra","Maffei, Camilla","Possenti, Stefano","Zambetti, Nicole","Moscato, Marianna","Venturini, Margherita","Affatato, Stefania","Gaggiotti, Mario","Bossini, Nicola","Scolari, Francesco"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354634","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.kint.2020.04.002","keywords":["acute kidney injury","inflammation","tocilizumab","transplantation"],"e_drugs":["Hydroxychloroquine","tocilizumab","Methylprednisolone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495273402368,"score":172.50526},{"pmid":32354637,"pmcid":"PMC7142878","title":"COVID-19 infection in kidney transplant recipients.","text":["COVID-19 infection in kidney transplant recipients.","By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected people from 177 countries and caused 11,252 reported deaths worldwide. Little is known about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney transplantation recipients, who may be at high-risk due to long-term immunosuppression, comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a six-week period in three south London hospitals. Two of seven patients presented within three months of transplantation. Overall, two were managed on an out-patient basis, but the remaining five required hospital admission, four in intensive care units. All patients displayed respiratory symptoms and fever. Other common clinical features included hypoxia, chest crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and troponin levels occurred in severe cases and likely prognostic. Immunosuppression was modified in six of seven patients. Three patients with severe disease were diabetic. During a three week follow up one patient recovered, and one patient died. Thus, our findings suggest COVID-19 infection in kidney transplant patients may be severe, requiring intensive care admission. The symptoms are predominantly respiratory and associated with fever. Most patients had their immunosuppression reduced and were treated with supportive therapy.","Kidney Int","Banerjee, Debasish","Popoola, Joyce","Shah, Sapna","Ster, Irina Chis","Quan, Virginia","Phanish, Mysore","32354637"],"abstract":["By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected people from 177 countries and caused 11,252 reported deaths worldwide. Little is known about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney transplantation recipients, who may be at high-risk due to long-term immunosuppression, comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a six-week period in three south London hospitals. Two of seven patients presented within three months of transplantation. Overall, two were managed on an out-patient basis, but the remaining five required hospital admission, four in intensive care units. All patients displayed respiratory symptoms and fever. Other common clinical features included hypoxia, chest crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and troponin levels occurred in severe cases and likely prognostic. Immunosuppression was modified in six of seven patients. Three patients with severe disease were diabetic. During a three week follow up one patient recovered, and one patient died. Thus, our findings suggest COVID-19 infection in kidney transplant patients may be severe, requiring intensive care admission. The symptoms are predominantly respiratory and associated with fever. Most patients had their immunosuppression reduced and were treated with supportive therapy."],"journal":"Kidney Int","authors":["Banerjee, Debasish","Popoola, Joyce","Shah, Sapna","Ster, Irina Chis","Quan, Virginia","Phanish, Mysore"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354637","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.kint.2020.03.018","keywords":["covid-19","sars-cov-2 infection","immunosuppression","kidney transplantation"],"locations":["London","hypoxia","ferritin"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Case Report"],"weight":1,"_version_":1666138495195807744,"score":166.69118}]}